There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vaxart (VXRT) and Replimune Group (REPL) with bullish sentiments.
Vaxart (VXRT)
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 14.1% and a 49.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vaxart with a $14.50 average price target.
See today’s analyst top recommended stocks >>
Replimune Group (REPL)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group, with a price target of $30.00. The company’s shares closed last Friday at $23.70, close to its 52-week high of $26.22.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of 40.7% and a 71.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group with a $30.40 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
